Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197591 | 1.00 | NR1H4 (0.63) | NR1H4CYP2C9CYP3A4KCNH2CYP2D6 | |
| SCHEMBL197589 | 1.00 | NR1H4 (0.63) | NR1H4CYP2C9CYP3A4KCNH2CYP2D6 | |
| SCHEMBL197263 | 0.96 | NR1H4 (0.65) | NR1H4CYP2C9CYP3A4KCNH2CYP2D6 | |
| SCHEMBL197593 | 0.96 | NR1H4 (0.65) | NR1H4CYP2C9CYP3A4KCNH2CYP2D6 | |
| SCHEMBL197212 | 0.92 | NR1H4 (0.55) | NR1H4CYP2C9CYP3A4KCNH2CYP2D6 | |
| SCHEMBL198578 | 0.91 | PDE6D (0.53) | NR1H4CYP2C9CYP3A4KCNH2CYP2D6 | |
| SCHEMBL197192 | 0.91 | NR1H4 (0.63) | NR1H4CYP2C9CYP3A4KCNH2CYP2D6 | |
| SCHEMBL198994 | 0.90 | NR1H4 (0.64) | NR1H4CYP2C9CYP3A4KCNH2CYP2D6 | |
| SCHEMBL197362 | 0.89 | NR1H4 (0.67) | NR1H4CYP2C9CYP3A4KCNH2CYP2D6 | |
| SCHEMBL197218 | 0.89 | NR1H4 (0.65) | NR1H4CYP2C9CYP3A4KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321282-B1 | NEW BENZIMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-03-27 | — | — | EP | claimed |
| US-8088930-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | claimed |
| US-20100063101-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | US | claimed |
| EP-2321282-B1 | NEW BENZIMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2013-03-27 | — | — | EP | disclosed |
| US-8088930-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100063101-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063101-A1 | NEW BENZIMIDAZOLE DERIVATIVES | CYP3A7, ECI1, CYP2B6 | NR1H4 292/4885CYP2C9 34/4885CYP3A4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.